The BioCentury Show

Hosted by BioCentury

Business Science

Website RSS feed LinkedIn YouTube

Episodes

Latest episode

Jul 2026

Language

EN-US

About the show

Tune in to BioCentury’s in-depth conversations with global leaders who are advancing the future of medicine. Join our Senior Editors in face-to-face discussions with scientific KOLs, top executives, VCs, and key policymakers, dissecting the most urgent public health issues. The BioCentury Show is THE only place where BioCentury’s experts join top innovators and global influencers to show how science is being turned into medicine. Don't miss this event, every two weeks, now available as a video webcast or audio podcast .

Listen to episodes

60 recent

July 23, 2026Episode 11540 min

Ep. 115 - Initiate's Owens on what it takes to be AI-native

As AI becomes increasingly commoditized, Initiate Ventures' Jessica Owens argues healthcare and life sciences companies need to use it to solve historically intractable problems, not just streamline workflows. On The BioCentury Show, Owens breaks down how she evaluates founders, when Initiate chooses to fund versus co-found a company, and why she believes proprietary data now matters more than any proprietary model.Owens also discusses gaps in evidence generation for diagnostics, and closes with a look at MASH, arguing that better non-invasive fibrosis staging will become increasingly critical as more GLP-1 combination therapies reach patients.View full story: https://www.biocentury.com/article/660203#AI #VentureCapital #Diagnostics #HealthTech #DrugDevelopment00:00 - Introduction01:15 - Initiate Ventures' Thesis07:04 - What Makes Founders Fundable17:36 - Defining AI Native Healthcare23:20 - Diagnostics & Evidence Generation36:44 - Non-Invasive Fibrosis Testing

July 10, 2026Episode 11441 min

Ep. 114 - Roivant’s Matt Gline on commercial launches and the future of the vant model

Roivant CEO Matt Gline calls the company’s move beyond spinning out subsidiary “vants” to concentrating on late-stage programs and commercial launches less a pivot than an evolution toward an original goal, which could soon be realized with the approval and launch of brepocitinib this year.In conversation with Lindsay Martin on The BioCentury Show, Gline discussed how Roivant’s initial hub-and-spoke approach has provided the foundation needed for the company to develop and commercialize its portfolio now, including lead program JAK-1/TYK2 inhibitor brepocitinib. Gline also discussed how he views AI at Roivant and more broadly in biopharma R&D, the science behind Roivant’s next most advanced program, Phase III anti-FcRN mAb imeroprubart and the lessons he’s taking from a “graduating class” of biotechs that have launched programs, like Alnylam and Argenx S.E. View full story: https://www.biocentury.com/article/660059#DrugDevelopment #BiotechInnovation #Commercialization #ArtificialIntelligence #BiopharmaStrategy00:00 - Introduction00:42 - Roivant’s Evolution09:19 - AI in R&D17:48 - Lead Asset Brepocitinib28:23 - Anti-FcRN mAb Imeroprubart32:23 - China37:55 - What’s Next for Roivant

June 25, 2026Episode 11335 min

Ep. 113 - Frank Jiang on Hengrui’s rise and China’s new era of biopharma dealmaking

Launched in the 1970s as a generics company, Hengrui has become China’s leading innovator in R&D and dealmaking, with more than 100 NMEs in the pipeline and broad alliances with GSK and BMS. Under the leadership of Frank Jiang, EVP and chief strategy officer, Hengrui is engaging in a range of dealmaking and using its partnerships as stepping stones toward its goal of becoming one of the top biopharma companies in the world.In conversation with Executive Editor Jeff Cranmer on The BioCentury Show, Jiang describes the evolution of China’s biotech ecosystem — and Hengrui's — toward first-order innovation and the changing nature of deals in China, from straightforward licensing deals with “safe money” to NewCo deals and “co-co” partnerships.View full story: https://www.biocentury.com/article/659912#ChinaBiotech #BiopharmaInnovation #DrugDevelopment #StrategicPartnerships #GlobalBiotech00:00 - Introduction01:32 - Evolution of China Biotech08:43 - China Deals17:23 - Hengrui’s Evolution24:43 - Shareholder Base26:42 - Deals

June 18, 2026Episode 11240 min

Ep. 112 - Chris Arendt on rebuilding Takeda for AI

Chris Arendt, CSO of Takeda, likens the AI overhaul at the pharma to gutting and rebuilding an old house, from the plumbing and electrical up, while you’re still living there. In a Fireside Chat at Grand Rounds U.S. in Seattle, Arendt sat down with Editor in Chief Simone Fishburn to discuss how Takeda is integrating AI across R&D, in and beyond the science, while still executing on the active programs in drug development.View full story: https://www.biocentury.com/article/659807#ArtificialIntelligence #PharmaInnovation #DrugDevelopment #DigitalTransformation #ResearchAndDevelopment00:00 - Introduction02:07 - Revamping Takeda for AI19:03 - Teams & Talent26:43 - Alliances32:50 - Q&A

June 12, 2026Episode 11136 min

Ep. 111 - McGill's Angela Genge on why ALS drug development is turning a corner

ALS drug development has long been hampered by heterogeneity, but Angela Genge — neurologist at McGill University and CMO of AL-S Pharma — argues the field is getting closer to making that heterogeneity tractable. On The BioCentury Show, Genge discusses progress in pathway prioritization, progression-rate prediction, and endpoint standardization with BioCentury's Selina Koch.On the biology side, Genge expects the field to converge on a small number of high-priority pathways. SOD1 is the first validated example, and AL-S Pharma is now testing whether misfolded SOD1 marks a treatable subset of sporadic ALS. On biomarkers, she's optimistic a TDP-43 marker could arrive within two years.View full story: https://www.biocentury.com/article/659713 #ALS #DrugDevelopment #ClinicalTrials #Biomarkers #ALSResearch00:00 - Introduction02:03 - ALS Mechanistic Diversity06:13 - Trial Design Challenges16:52 - Biomarker Toolkit Update24:20 - ALS Pharma & SOD1

May 28, 2026Episode 11037 min

Ep. 110 - Richard Pops on Three Decades in Biotech: Drug pricing, FDA and China

Richard Pops has lived the biotech roller coaster over three decades as CEO of Alkermes: an IPO, M&A, near-death events for his company, FDA setbacks, battles with an activist investor, and the satisfaction of knowing that millions of patients have benefited from the company’s medicines. He has led PDUFA reauthorization negotiations for industry, chaired BIO, and advocated for the interests of mid-sized biotechs.As Pops prepares to retire as CEO (he will remain chairman), he spoke with BioCentury Washington Editor Steve Usdin about the ways policy and economics shape the development of medicines. Pops discussed the impact of the Trump administration’s most favored nation (MFN) drug pricing policy and the Inflation Reduction Act (IRA), concerns about FDA’s loss of talent, and competition and collaboration with China’s life sciences sector.View full story: https://www.biocentury.com/article/659601#DrugPricing #BiotechLeadership #FDAPolicy #LifeSciencesPolicy #DrugDevelopment00:00 - Introduction01:40 - Alkermes’ Evolution05:12 - PBMs, Pricing & Access10:54 - IRA18:14 - MFN24:36 - PDUFA Negotiations28:05 - FDA Staffing31:40 - China & U.S. Policy

May 15, 2026Episode 10936 min

Ep. 109 - Mind the Gap: Karen Knudsen on Fixing Cancer Drug Development

Karen Knudsen, CEO of the Parker Institute for Cancer Immunotherapy, believes the central problem in cancer drug development is not discovery, but a broken “translational middle.”In a wide-ranging interview on The BioCentury Show with BioCentury Washington Editor Steve Usdin, Knudsen discussed the Parker Institute’s focus on accelerating the path from scientific breakthrough to medical impact.As it approaches its tenth anniversary, the institute has deployed about $400 million, catalyzing roughly $4 billion in follow-on investment across 17 companies.View full story: https://www.biocentury.com/article/659476#CancerImmunotherapy #TranslationalScience #DrugDevelopment #Biopharma #CancerResearch00:00 - Introduction01:34 - Optimizing Translation07:42 - Training the Immune System16:33 - China’s Opportunity20:50 - Need for a Cancer Strategy24:40 - Enhancing Cancer Survivorship27:55 - Scientific Foundation Under Threat

May 1, 2026Episode 10833 min

Ep. 108 - Rethinking Discovery: Chris Hollowood on Causal Biology and Syncona’s Strategy

A paradigm shift in research tools, combined with large-scale unbiased screening, has positioned the biopharma industry not only to rethink target discovery, but also to execute more faithfully on causal biology, according to Syncona CEO Chris Hollowood.Hollowood spoke on The BioCentury Show with Editor in Chief Simone Fishburn about how discovery is evolving, why causal biology has been stuck in a loop of circularity, and where the U.K. investor is headed. He also discussed the firm’s approach to gene therapy investments, how it is surmounting the field’s challenges and Syncona’s pivot last year, with a portfolio shift from 25% to over 85% clinical-stage companies.View full story: https://www.biocentury.com/article/659341#CausalBiology #GeneTherapy #BiotechInvesting #DrugDiscovery #ClinicalStage00:00 - Introduction01:06 - Rational Target Discovery16:48 - Gene Therapy23:15 - Syncona’s Strategy

April 17, 2026Episode 10737 min

Ep. 107 - Forbion’s Slootweg on Europe Biotech, NewCos From Asia and Green Investing

The European biotech ecosystem has gone through a substantial maturation process over the past 20 years, as VC funds such as Forbion have experienced exponential growth to fund the region’s innovation. But Forbion co-founder and managing director Sander Slootweg says there’s still more that can be done to fund future European innovations and improve Europe’s competitiveness globally.“We’ve observed in Europe that although we see great science, and we’ve been able to build great companies, in terms of the absolute magnitude of the ecosystem, we’re still lagging behind the U.S., and also China is coming up quickly,” Slootweg said in conversation with BioCentury's Stephen Hansen.View full story: https://www.biocentury.com/article/659150#EuropeanBiotech #VentureCapital #BiotechFunding #Bioeconomy #GlobalInnovation00:00 - Introduction01:34 - Forbion’s growth05:35 - Deal flow in Europe10:20 - Green Investing14:24 - Sourcing Asia Deals22:20 - Unlocking the EU’s Capital27:54 - Speeding Up Trials30:13 - Building a Thriving EU Market34:38 - Central & Eastern Europe

April 3, 2026Episode 10633 min

Ep. 106 - Can the U.K. Capture Biotech Value? Daniel Mahony on Growth, Pricing and Reform

The U.K. is excellent at invention and science, and creating institutions to further innovation, but poor at capturing their economic value, says Daniel Mahony, a problem that various forces in the U.K. are now putting serious efforts into solving.Mahony, one of the major influential figures in U.K. biotech, is a senior partner in growth investments at Novo Holdings, and was until December chair of the U.K.’s BioIndustry Association (BIA). In conversation with BioCentury Editor in Chief Simone Fishburn on The BioCentury Show, Mahony discussed the future of U.K. and European biotech, and the intersection of reforms related to financing and clinical trials, as well as the need for a rethink on drug pricing.View full story: https://www.biocentury.com/article/658997#UKBiotech #BiotechInnovation #DrugPricing #HealthcareReform #LifeSciencesPolicy00:00 - Introduction01:40 - U.K. Clinical Trial Reform04:23 - Funding U.K. Biotech10:40 - Propagating Innovation15:08 - Measuring Progress18:22 - Drug Pricing22:40 - Scaling Europe’s Biotechs25:16 - AI in Biotech